A wide range of new opportunities in global healthcare have been created by a record level of investments across the biopharma industry. "Venture-capital funding, initial public offerings, and secondary offerings by already-public companies led to $88 billion in new equity in 2020, with most going toward emerging biopharma companies," according to the Drug, Chemical & Associated Technologies Association, data from investment firm Jefferies Financial Group Inc.1 This will likely result in a flurry of collaborations with contract development and manufacturing organizations (CDMOs) to help fill expertise and resource gaps within these developing companies.
Whether you are just entering the field or responding to the influx of competition, you must know how to vet potential providers, especially for process development services. This critical step is a key factor in determining your drug program’s overall success.
A panel of experts with experienced and diverse perspectives discussed this topic during an online event titled Best Practices for Outsourcing Process Development, where four themes surfaced that may help drive the best outcomes with your process development service provider.